Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): An open-label, randomised, controlled trial

The Lancet

Volumn 384, Issue 9948, 2014, Pages 1118-1127

  Rintoul, Robert C ^a   Ritchie, Andrew J ^b   Edwards, John G ^c   Waller, David A ^d   Coonar, Aman S ^a   Bennett, Maxine ^e   Lovato, Eleonora ^f   Hughes, Victoria ^a   Fox Rushby, Julia A ^f   Sharples, Linda D ^a,e,g  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b NHS Foundation Trust   (United Kingdom)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

^d GLENFIELD HOSPITAL   (United Kingdom)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f BRUNEL UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TALC PLEURODESIS; VIDEO ASSISTED THORACOSCOPIC PARTIAL PLEURECTOMY; CLINICAL TRIAL; COMPARATIVE STUDY; COST; ECONOMICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MESOTHELIOMA; MORTALITY; MULTICENTER STUDY; PLEURAL NEOPLASMS; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; VIDEO ASSISTED THORACOSCOPIC SURGERY;

TALC;

AGED; COSTS AND COST ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; PLEURODESIS; QUALITY-ADJUSTED LIFE YEARS; TALC; THORACIC SURGERY, VIDEO-ASSISTED; TREATMENT OUTCOME;

EID: 84908329536     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60418-9     Document Type: Article

References (31)

1. J Peto, JT Hodgson, FE Matthews, JR Jones Continuing increase in mesothelioma mortality in Britain Lancet 345 1995 535 539
2. JT Hodgson, DM McElvenny, AJ Darnton, MJ Price, J Peto The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050 Br J Cancer 92 2005 587 593
3. J Peto, A Decarli, C La Vecchia, F Levi, E Negri The European mesothelioma epidemic Br J Cancer 79 1999 666 672
4. NJ Vogelzang, JJ Rusthoven, J Symanowski et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
5. A Bottomley, R Gaafar, C Manegold the EORTC Lung-Cancer Group the National Cancer Institute, Canada Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study J Clin Oncol 24 2006 1435 1442
6. D Rice, V Rusch, H Pass for the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group J Thorac Oncol 6 2011 1304 1312
7. T Treasure, L Lang-Lazdunski, D Waller for the MARS trialists Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study Lancet Oncol 12 2011 763 772
8. RM Flores, HI Pass, VE Seshan et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients J Thorac Cardiovasc Surg 135 2008 620 626
9. L Lang-Lazdunski, A Bille, R Lal et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma J Thorac Oncol 7 2012 737 743
10. E Teh, F Fiorentino, C Tan, T Treasure A systematic review of lung-sparing extirpative surgery for pleural mesothelioma J R Soc Med 104 2011 69 80
11. A Nakas, AE Martin Ucar, JG Edwards, DA Waller The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma Eur J Cardiothorac Surg 33 2008 83 88
12. JC Halstead, E Lim, RM Venkateswaran, SC Charman, M Goddard, AJ Ritchie Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma Eur J Surg Oncol 31 2005 314 320
13. D Curran, T Sahmoud, P Therasse, J van Meerbeeck, PE Postmus, G Giaccone Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 1998 145 152
14. VW Rusch A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group Chest 108 1995 1122 1128
15. P Kind The EuroQoL instrument: an index of health-related quality of life B Spilker Quality of life and pharmacoeconomis in clinical trials 2nd edn. 1996 Lippincott-Raven Publishers Philadelphia, PA 191 201
16. NK Aaronson, S Ahmedzai, B Bergman et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
17. A Cantó, R Guijarro, A Arnau, J Galbis, M Martorell, R García Aguado Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions Thorac Cardiovasc Surg 45 1997 16 19
18. L Curtis Unit costs of health and social care 2011 2011 Personal and Social Services Research Unit, University of Kent Canterbury, Kent
19. P Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
20. E Lydick, RS Epstein, D Himmelberger, CJ White Area under the curve: a metric for patient subjective responses in episodic diseases Qual Life Res 4 1995 41 45
21. C Cao, DH Tian, KA Pataky, TD Yan Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma Lung Cancer 81 2013 319 327
22. AS Pickard, MP Neary, D Cella Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer Health Qual Life Outcomes 5 2007 70
23. G Antunes, E Neville, J Duffy, N Ali the Pleural Diseases Group Standards of Care Committee British Thoracic Society BTS guidelines for the management of malignant pleural effusions Thorax 58 suppl 2 2003 ii29 ii38
24. NM Rahman, NJ Ali, G Brown the British Thoracic Society Pleural Disease Guideline Group Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010 Thorax 65 suppl 2 2010 ii54 ii60
25. F Rodriguez-Panadero, A Montes-Worboys Mechanisms of pleurodesis Respiration 83 2012 91 98
26. S Bielsa, P Hernández, F Rodriguez-Panadero, T Taberner, A Salud, JM Porcel Tumor type influences the effectiveness of pleurodesis in malignant effusions Lung 189 2011 151 155
27. ET Fysh, SK Tan, CA Read et al. Pleurodesis outcome in malignant pleural mesothelioma Thorax 68 2013 594 596
28. American Thoracic Society Management of malignant pleural effusions Am J Respir Crit Care Med 162 2000 1987 2001
29. National Institute for Health and Care Excellence NICE consults on new draft recommendations for lung cancer drug http://www.nice.org.uk/newsroom/pressreleases/CrizotinibACD.jsp (accessed Sept 15, 2013).
30. Asbestos Diseases Research Institute Guidelines for the diagnosis and treatment of malignant pleural mesothelioma 2013 Asbestos Diseases Research Institute Sydney, Australia
31. British Thoracic Society Standards of Care Committee BTS statement on malignant mesothelioma in the UK, 2007 Thorax 62 suppl 2 2007 ii1 i19